Southern Archipelago (A33) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 Nov, 2026Executive summary
Q1 2026 revenue fell 47% YoY to S$643k; net loss narrowed to S$525k from S$587k.
Challenging Indonesian market conditions and slower-than-expected sterilisation sales ramp-up weighed on performance; capacity expansion is complete.
Material going-concern uncertainty remains amid net current liabilities, a loan covenant breach and ongoing fundraising efforts.
Financial highlights
Revenue was S$643k versus S$1.217m in 1Q2025; all reported revenue came from sterilisation services.
Net loss was S$525k versus S$587k; total comprehensive loss was S$714k versus S$366k, including a S$189k currency translation loss versus a S$221k gain.
Other gains were S$121k versus prior-year net losses of S$387k; the prior period included a one-off S$828k loss on liquidation of a dormant subsidiary.
Depreciation rose 45% YoY to S$271k, mainly reflecting sterilisation expansion costs; finance costs rose to S$104k from S$85k on additional bank and shareholder loans.
Income tax expense fell to S$50k from S$141k, reflecting lower chargeable income and a deferred tax credit.
Outlook and guidance
Sterilisation capacity expansion is complete; sales ramp-up is slower than expected, but management expects positive operating cash flow as customer-development efforts mature.
Management is targeting new sterilisation customers to recover volumes and is exploring fundraising options for additional working capital.
Substantial shareholders have undertaken to provide financial support for at least 12 months from approval of FY2025 statements.
Latest events from Southern Archipelago
- Sterilisation recovery continues, but liquidity strains and a covenant breach cloud the outlook.A33
Q3 2026 - Revenue and net profit improved, but liquidity and diversification remain key challenges.A33
H2 2023 - A return to modest profit meets weaker revenue and widening working-capital pressure.A33
H1 2024 - Sterilisation expansion continued as lower revenue, a net loss and tight liquidity shaped FY2024.A33
H2 2024 - Sterilisation growth plans amid a S$566k loss, negative working capital and covenant risk.A33
H1 2025 - Revenue fell 17.8%; upgraded capacity meets a strained balance sheet and recovery test.A33
H2 2025 - Sterilisation rebounded in 2Q, but liquidity pressure and a loan covenant breach persist.A33
H1 2026